Treatment of decrease in hemoglobin levels by Unani medicine Majoon Khabs-ul-Hadeed

Clinical Validation of Unani Pharmacopoeial Formulation Majoon Khabs-ul-Hadeed in SÅ«â?? al-Qinya (Iron deficiency Anaemia)

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2020/07/026569

Enrollment

300

Registered

2020-07-14

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: D508- Other iron deficiency anemias

Interventions

Intervention1: Majoon Khabs-ul-Hadeed: 5 gm Twice daily Orally to be taken with water after meals for 12 weeks Control Intervention1: Nil: Nil

Eligibility

Inclusion criteria

Inclusion criteria: Patients having mild (10.0-11.9 g/dl) to moderate (7.0-9.9 g/dl) Anaemia

Exclusion criteria

Exclusion criteria: 1. Patients having severe Anaemia (below 7gm/dl) 2. Patients with excessive bleeding e.g. bleeding piles, menorrhagia, metrorrhagia etc 3. Known cases of chronic diseases on long term treatment. 4. Patients with concurrent serious hepatic, cardiac, renal dysfunction. 5. Pregnant and lactating women

Design outcomes

Primary

Measure	Time frame
Improvement in signs and symptoms of SÅ«â?? al-Qinya (Iron deficiency Anaemia)Timepoint: 12 weeks	—

Secondary

Measure	Time frame
Haematological and biochemical assessment for safety assessmentTimepoint: Investigations will be done at 0, 4, 8, 12 weeks	—

Countries

India

Contacts

Public ContactDr Pradeep Kumar

Central Council for Research in Unani Medicine (CCRUM)

ccrum507@rediffmail.com9213511298

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026